Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Moderate Buy” by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has been given an average rating of “Moderate Buy” by the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $75.00.

KROS has been the subject of a number of research reports. Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Truist Financial cut their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Guggenheim downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Finally, BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th.

Keros Therapeutics Trading Down 2.2 %

Shares of NASDAQ:KROS opened at $14.56 on Friday. The firm has a market cap of $589.78 million, a price-to-earnings ratio of -2.79 and a beta of 1.43. The stock’s 50-day moving average price is $41.71 and its two-hundred day moving average price is $48.32. Keros Therapeutics has a 12-month low of $13.96 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the company earned ($1.33) earnings per share. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, research analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Keros Therapeutics by 3.8% during the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the period. Alkeon Capital Management LLC grew its holdings in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP boosted its position in Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.